Skip Navigation



JAC Advance Access published online on February 25, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg154
© 2003 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/4/1025    most recent
dkg154v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hammerschlag, M. R.
Right arrow Articles by Bukofzer, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hammerschlag, M. R.
Right arrow Articles by Bukofzer, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 The British Society for Antimicrobial Chemotherapy

Brief report

Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae

Margaret R. Hammerschlag 1*, Tamara Reznik 1, Patricia M. Roblin 1, Julio Ramirez 2, James Summersgill 2, Stanley Bukofzer 3

1 Departments of Pediatrics and Medicine, State University of New York Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, New York, NY 11203-2098
2 Department of Medicine, University of Louisville, Louisville, KY
3 Abbott Laboratories, 200 Abbott Park Road, Abbott Park, IL, USA

* Corresponding author. E-mail: mhammerschlag{at}pol.net.

Received 22 October 2002 ; revised 13 December 2002 ; accepted 15 January 2003

Abstract

Nasopharyngeal specimens for culture of Chlamydia pneumoniae were obtained from patients with community-acquired pneumonia enrolled in a randomized study comparing the novel ketolide antibiotic ABT-773 at a dose of 150 mg once a day to 150 mg twice a day, by mouth for 10 days. C. pneumoniae was eradicated from the nasopharynx of 10 of 10 (100%) microbiologically evaluable patients. MICs and MBCs for 13 isolates of C. pneumoniae from 12 patients obtained before and after therapy were performed against ABT-773. The MIC90 and MBC90 of ABT-773 were 0.015 mg/L.

Keywords: chlamydia, C. pneumoniae, ketolide
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CLIN PEDIATRHome page
S. I. Pelton and M. R. Hammerschlag
Overcoming Current Obstacles in the Management of Bacterial Community-Acquired Pneumonia in Ambulatory Children
Clinical Pediatrics, January 1, 2005; 44(1): 1 - 17.
[PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. E. Conte Jr., J. A. Golden, J. Kipps, and E. Zurlinden
Steady-State Plasma and Intrapulmonary Pharmacokinetics and Pharmacodynamics of Cethromycin
Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3508 - 3515.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. R. Hammerschlag and P. M. Roblin
The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae
J. Antimicrob. Chemother., July 1, 2004; 54(1): 281 - 282.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. R. Reinert
Clinical efficacy of ketolides in the treatment of respiratory tract infections
J. Antimicrob. Chemother., June 1, 2004; 53(6): 918 - 927.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
N. Miyashita, H. Fukano, K. Yoshida, Y. Niki, and T. Matsushima
In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae
J. Antimicrob. Chemother., September 1, 2003; 52(3): 497 - 499.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.